| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3218451
Max Phase: Preclinical
Molecular Formula: C8H13N2O6P
Molecular Weight: 264.17
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(C)c1oc(N)nc1C(=O)OCP(=O)(O)O
Standard InChI: InChI=1S/C8H13N2O6P/c1-4(2)6-5(10-8(9)16-6)7(11)15-3-17(12,13)14/h4H,3H2,1-2H3,(H2,9,10)(H2,12,13,14)
Standard InChI Key: JLMJESVNSZQEKX-UHFFFAOYSA-N
Associated Targets(Human)
FBP1 Tchem Fructose-1,6-bisphosphatase (1199 Activities)
Associated Targets(non-human)
Fbp1 Fructose-1,6-bisphosphatase (106 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Rattus norvegicus (775804 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 264.17 | Molecular Weight (Monoisotopic): 264.0511 | AlogP: 0.67 | #Rotatable Bonds: 4 |
| Polar Surface Area: 135.88 | Molecular Species: ACID | HBA: 6 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 1.42 | CX Basic pKa: 0.57 | CX LogP: -0.07 | CX LogD: -2.18 |
| Aromatic Rings: 1 | Heavy Atoms: 17 | QED Weighted: 0.53 | Np Likeness Score: -0.05 |
References
| 1. Dang Q, Kasibthatla SR, Jiang T, Taplin F, Gibson T, Potter SC, van Poelje PD, Erion MD. (2011) Oxazole phosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity, 2 (4): [10.1039/C0MD00269K] |
Source
Source(1):